换一批
换一批Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
第一作者：
Weiran,Liu
第一单位：
Department of Anesthesiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
作者：
主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);细胞系, 肿瘤(Cell Line, Tumor);细胞运动(Cell Movement);细胞增殖(Cell Proliferation);疾病模型, 动物(Disease Models, Animal);抗药性, 肿瘤(Drug Resistance, Neoplasm);酶激活(Enzyme Activation);女(雌)性(Female);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);肺肿瘤(Lung Neoplasms);小鼠(Mice);分子靶向治疗(Molecular Targeted Therapy);突变(Mutation);萘类(Naphthalenes);原癌基因蛋白质类p21(ras)(Proto-Oncogene Proteins p21(ras));信号传导(Signal Transduction);末端转移酶端粒(Telomerase);端粒(Telomere);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.18632/oncotarget.10162
PMID
27329725
发布时间
2018-11-13
- 浏览12
Oncotarget
179-190页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
